Proteomics can improve breast cancer treatment

July 22, 2013

Researchers at Karolinska Institutet in Sweden have identified a protein that could help physicians decide what type of therapy patients with hormone driven breast cancer should go through. In a study, published in Nature Communications, they show that high levels of a protein called retinoic acid receptor alpha (RARA) in breast tumors can be linked to an insufficient response to the cancer drug tamoxifen. The findings are based on a novel proteomics technique, developed at the Science for Life Laboratory.

About 80% of all breast cancer tumors depend on the to grow. Estrogen acts by binding to so-called estrogen receptors (ER) in cancer cell. Substances that block the action of estrogen have been shown to prevent the growth of many of these tumors. The goal after surgery is to prevent the growth of any cancer cell that might still be in the body after surgery. A common drug used for this purpose is , which blocks the action of estrogen in the by binding to the ER of .

"This drug has been shown to be very effective, however about one third of the patients do not respond to treatment and their breast tumors return", says Dr. Henrik Johansson, first author of the Nature Communications publication. "In our study, we show that in these cases the often contain high amounts of RARA, which indicates that this protein has an important role in hormone driven breast cancer."

Under the management of Associate Professor Janne Lehtiö, the research team behind the current study has put a lot of effort into studying resistance mechanism in breast cancer. This time researchers aimed to find markers that separate the groups of patients that will benefit from tamoxifen treatment from those that do not. Amongst other things, they studied protein quantities in breast cancer cell lines and made a comparison between cell lines resistant and sensitive to tamoxifen, respectively.

"In our laboratory we have developed a method that improves protein detection, which makes it possible to detect small differences in protein levels for a large number of proteins in tumor cells", says Dr. Janne Lehtiö. "With this method we found many interesting proteins, of which one is RARA."

The team continued to investigate RARA in two independent groups of breast cancer patients. The results show that patients with breast cancer tumors containing high levels of RARA had an increased risk of tumor recurrence, compared to patients with low levels of the protein.

"The relationship between RARA and ER is complex, and something we will continue to investigate", says Janne Lehtiö. "However, we believe that we have identified a way to tailor treatment to fit the individual patient, and that there also are other possibilities for technology development, which may benefit public health care in the future."

The technique used in this project, so-called quantitative mass spectrometry-based proteomics, has been developed by the researchers in collaboration with the Swedish pharmaceutical company GE Healthcare. Janne Lehtiö's research group is based at the Department of Oncology-Pathology at Karolinska Institutet as well as at the Swedish national research facility Science for Life Laboratory. Researchers from Sahlgrenska Academy in Gothenburg, Linköping University and Karolinska University Hospital, Solna in Stockholm County also took part in the study. The Swedish Research Council, the European Union's seventh frame program and the Swedish Cancer Society, amongst other bodies, funded the research.

Explore further: Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors

More information: Nature Communications, online 19 July 2013, doi: 10.1038/ncomms3175

Related Stories

Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors

June 15, 2013
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute ...

Researcher identifies breast cancer fighting hormone

May 24, 2013
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment

June 29, 2013
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after ...

Coffee may help prevent breast cancer returning, study finds

April 25, 2013
Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found. Patients who took the pill, along with two or more cups ...

Alternative target for breast cancer drugs

July 19, 2013
Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today ...

Studies show increasing evidence that androgen drives breast cancer

April 10, 2013
Estrogen and progesterone receptors, and the gene HER2 – these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.